Ketamine vs ECT for Severe Depression: Meta-Analysis Shifts Clinical Debate

Meta-Analysis Finds Comparable Efficacy for Ketamine and ECT in Severe Treatment-Resistant Depression

A September 2026 systematic review and meta-analysis, published on OpenAlex, provides the most comprehensive head-to-head synthesis to date of intravenous ketamine versus electroconvulsive therapy (ECT) for severe treatment-resistant depression (TRD). Analyzing 18 studies with 1,388 participants—including 12 direct comparisons—the review concludes that, overall, ketamine and ECT yield similar response and remission rates in severe TRD. Pooled response rates showed no significant difference (risk ratio [RR] 1.13; 95% confidence interval [CI] 0.85–1.49), and remission rates were likewise statistically indistinguishable (RR 1.16; 95% CI 0.77–1.76).

However, the analysis reveals that this apparent equivalence is not uniform across all patient groups. Subgroup analysis and sensitivity testing (notably omitting the influential ELEKT-D trial) showed ECT's superiority in hospitalized, more severely ill patients, while ketamine was non-inferior in ambulatory, less severe cases. These findings directly challenge the notion of interchangeability between the two interventions and suggest that patient selection is critical for optimizing outcomes in TRD.

Mechanisms, Cognitive Outcomes, and Patient Profiles

Ketamine and ECT differ fundamentally in their mechanisms and side effect profiles, which influences their suitability for specific patient populations. ECT, a long-established intervention, induces generalized seizures under anesthesia and is associated with robust efficacy in psychotic or severely ill, often hospitalized patients. However, ECT is also linked to transient amnesia and musculoskeletal pain, and it carries significant stigma and logistical burdens.

Ketamine, administered as a subanesthetic intravenous infusion, acts primarily as an N-methyl-D-aspartate (NMDA) receptor antagonist, producing rapid antidepressant effects. The meta-analysis highlights a clear neurocognitive advantage for ketamine, particularly in ambulatory populations: delayed verbal recall scores declined far less with ketamine (mean −0.9 ± 1.1 T-score points) compared to ECT (mean −9.7 ± 1.2). This cognitive preservation is especially relevant for patients with pre-existing cognitive vulnerabilities or those who prioritize rapid functional recovery.

Importantly, the review identifies a non-obvious implication: the relative benefit of ketamine is most pronounced not in the most severely ill, but in those who are less acute, ambulatory, and without psychotic features. This effect modification—where the treatment effect depends on patient characteristics—explains much of the discordance in prior studies and underscores the need for individualized treatment planning.

Policy, Payer, and Research Implications

The findings of this meta-analysis are poised to shape clinical guidelines, insurance coverage, and regulatory frameworks for depression care. For payers and policymakers, the evidence supports the inclusion of ketamine as a viable alternative to ECT in specific patient populations, particularly those managed in outpatient settings without psychosis. This could accelerate the adoption of ketamine in psychiatric practice, especially as more clinics and providers seek to offer rapid-acting interventions for TRD.

Regulators and professional societies may update recommendations to reflect the nuanced evidence base, emphasizing stratified treatment pathways based on severity, setting, psychotic features, and cognitive risk. The review also highlights the urgent need for adequately powered, longer-duration randomized controlled trials (RCTs) with standardized continuation strategies and harmonized neurocognitive assessments. Notably, the high heterogeneity (I² > 80%) across studies and the low certainty of evidence for efficacy outcomes—downgraded for inconsistency and risk of bias—underscore the limitations of current data and the importance of further research.

One concrete example of policy impact: some insurers have historically denied ketamine coverage on the grounds of insufficient comparative evidence. This meta-analysis directly addresses that gap, providing a rationale for payer reconsideration—especially for patients who are not ideal ECT candidates.

Risks, Limitations, and Unknowns

Despite promising results, both ketamine and ECT carry significant risks and unresolved questions. Ketamine's principal liabilities include the brevity of its antidepressant effect (often days to weeks), uncertainties about long-term safety (notably cystitis and misuse potential), and dose-dependent dissociative and hemodynamic side effects. ECT, while effective, is limited by transient amnesia, the need for anesthesia, and persistent stigma among patients and providers.

The certainty of the evidence remains low to very low for efficacy outcomes, primarily due to study heterogeneity and potential bias. The review also notes that relapse and discontinuation rates did not differ significantly between modalities, but these findings are based on limited data. Longer-term outcomes, optimal continuation strategies, and real-world effectiveness in diverse populations remain open questions.

Looking Ahead: Toward Individualized Depression Care

The 2026 meta-analysis marks a turning point in the comparative evaluation of ketamine and ECT for severe TRD, providing a more granular evidence base to guide clinical and policy decisions. The key insight is that neither treatment is universally superior; rather, their relative advantages depend on patient-specific factors such as severity, setting, psychotic features, cognitive vulnerability, and personal preference. As the field moves toward more personalized approaches, future research should prioritize stratified RCTs and standardized outcome measures to refine treatment algorithms and maximize both efficacy and safety for patients with TRD.

Byline: Dr. Alex S. Morgan, MD, PhD. Reviewed by Dr. Lila Chen, MD, on 2026-10-01. Sources: OpenAlex meta-analysis (W7214772038), PRISMA 2020 guidelines, primary trial registries.